Tetracaine Hydrochloride

Manufacturer
Paragon BioTeck, Inc. | Bausch & Lomb Incorporated
Effective date
2019-03-12
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
legacy-cache
Hydrated at
2026-08-02 00:29:14

Label at a glance#

ProductTetracaine Hydrochloride
Active ingredientTETRACAINE HYDROCHLORIDE
Label structure15 sections

Indications and uses

Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic.

Dosage and administration

One drop topically in the eye(s) as needed.

Storage and handling

Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% is supplied as a sterile, aqueous, topical ophthalmic solution with a fill volume of 15 mL in a 15 mL low-density polyethylene plastic dropper bottle with a low-density polyethylene dropper tip and white polypropylene cap. NDC 42702-170-15 After opening, this product can be used until the expiration date stamped on the bottle. Storage : Store at 15°C to 25°C (...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% is indicated for procedures requiring

a rapid and short-acting topical ophthalmic anesthetic.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

One drop topically in the eye(s) as needed.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% is a clear, colorless, ophthalmic

solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Tetracaine Hydrochloride Ophthalmic Solution, USP, 0.5% should not be used in patients with a

history of hypersensitivity to any component of this preparation.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Corneal Injury with Intracameral Use

SPL UNCLASSIFIED SECTION

Not for injection or intraocular use. Do not use intracamerally because use of Tetracaine

Hydrochloride Ophthalmic Solution USP, 0.5% may lead to damage of the corneal endothelial

cells.

5.2 Corneal Toxicity

SPL UNCLASSIFIED SECTION

Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial

defects which may progress to permanent corneal damage.

5.3 Corneal Injury due to Insensitivity

SPL UNCLASSIFIED SECTION

Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental

injuries can occur due to insensitivity of the eye.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following serious ocular adverse reactions are described elsewhere in the labeling:

  • Corneal Injury with Intracameral Use [See Warnings and Precautions (5.1)]
  • Corneal Toxicity [See Warnings and Precautions (5.2)]
  • Corneal Injury due to Insensitivity [See Warnings and Precautions (5.3)]

The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliable estimate their frequency or establish a causal relationship to drug exposure.

Ocular Adverse Reactions

Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary

There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic

Solution USP, 0.5% in pregnant women. Animal developmental and reproductive toxicity studies

with tetracaine hydrochloride have not been reported in the published literature.

8.2 Lactation

LACTATION SECTION

Risk Summary

There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% is

excreted in human milk or to assess its effects on milk production/excretion. The developmental

and health benefits of breastfeeding should be considered along with the mother’s clinical need

for Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% and any potential adverse effects

on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5%.

8.3 Females and Males of Reproductive Potential

FEMALES & MALES OF REPRODUCTIVE POTENTIAL SECTION

No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% on

fertility are available.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Safety of Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% in the pediatric population

has been demonstrated in clinical trials. Efficacy of Tetracaine Hydrochloride Ophthalmic

Solution USP, 0.5% for use in pediatric patients has been extrapolated from adequate and well

controlled clinical trials in the adult population.

8.5 Geriatric Use

GERIATRIC USE SECTION

No overall differences in safety or effectiveness of Tetracaine Hydrochloride Ophthalmic

Solution USP, 0.5% have been observed between elderly and younger patients.

10 OVERDOSAGE

OVERDOSAGE SECTION

Prolonged use of a topical ocular anesthetic including Tetracaine Hydrochloride Ophthalmic

Solution USP, 0.5% may produce permanent corneal opacification and ulceration with

accompanying visual loss.

11 DESCRIPTION

DESCRIPTION SECTION

Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% is a sterile, clear, colorless, topical

local anesthetic for ophthalmic use containing tetracaine hydrochloride as the active

pharmaceutical ingredient.

Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-,

2-(dimethylamino) ethyl ester, monohydrochloride. Its chemical formula is C15H24N2O2 •

HCl and it is represented by the chemical structure:

chemstructure.jpg
chemstructure.jpg

Tetracaine hydrochloride is a fine, white, crystalline, odorless powder with a molecular weight of

300.82

Active ingredient: tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine)

Preservative: chlorobutanol 0.4%

Inactive ingredients: boric acid, potassium chloride, edetate disodium, water for injection USP.

Sodium hydroxide and/or hydrochloric acid may be added to adjust pH (3.7 – 6.0)

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal

impulses thereby affecting local anesthesia.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

The systemic exposure to tetracaine following topical ocular administration of Tetracaine

Hydrochloride Ophthalmic Solution USP, 0.5% has not been studied. Tetracaine hydrochloride is

metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the

published literature. Long-term animal studies have not been conducted to evaluate the

carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of

tetracaine hydrochloride on fertility have not been reported in the published literature.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

Topical administration of Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% results in

localized temporary anesthesia. The maximum effect is achieved within 10–20 seconds after

instillation, with efficacy lasting 10–20 minutes. Duration of effect can be extended with

repeated dosing. [See Warnings and Precautions (5.2) and Overdosage (10)].

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% is supplied as a sterile, aqueous,

topical ophthalmic solution with a fill volume of 15 mL in a 15 mL low-density polyethylene

plastic dropper bottle with a low-density polyethylene dropper tip and white polypropylene cap.

NDC 42702-170-15

After opening, this product can be used until the expiration date stamped on the bottle.

Storage: Store at 15°C to 25°C (59°F to 77°F). Protect from light. Do not use if solution

contains crystals, cloudy, or discolored.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Eye Care Precaution

Do not touch the dropper tip to any surface as this may contaminate the solution.

Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive for up to 20

minutes and that care should be taken to avoid accidental injuries.

Manufactured for:

Paragon BioTeck, Inc.

4640 SW Macadam Ave, Ste 80

Portland, OR 97239

Manufactured and Distributed by:

Bausch & Lomb

8500 Hidden River Pkwy

Tampa, FL 33637

Revised: March 2019

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL- Carton 15 mL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 42702-170-15

Paragon
BioTeck, Inc.

Tetracaine
Hydrochloride

Ophthalmic
Solution, USP
0.05%
(Sterile)

Rx Only

15 mL

carton.jpg
carton.jpg

FDA-Initiated Inactive NDC Indexing#

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
42702-17042702-170-15

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N210821-001TETRACAINE HYDROCHLORIDETETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-12

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
N210821-001AB1

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-1284e616aacf4f…
2026-08-18 06:07:402026-07N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-12caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-12011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-1231067a03dcf5…
2025-08-23 18:47 UTC2025-08N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-126a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-12fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-12b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-1203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-122680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-125bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-1279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-121e350fbaab3a…
2024-05-31 18:47 UTC2024-05N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-128072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-125c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-125d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-124b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMIC2019-03-1274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-1287673890dc5c…
2021-03-12 10:30 UTC2021-03N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-125aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-128869cabd3fbd…
2020-11-12 02:37 UTC2020-11N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMIC2019-03-12c0c555d07b60…
2019-12-14 00:12 UTC2019-12N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMIC2019-03-123f01610625f2…
2019-09-15 20:21 UTC2019-09N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMIC2019-03-12b00525d2431f…
2019-07-19 19:46 UTC2019-07N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMIC2019-03-12ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-126a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-121c564ffb4f44…
2023-12-20 04:57 UTC2023-12N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-129b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-123f0d92c62455…
2023-05-13 08:27 UTC2023-05N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12053a50430f4f…
2023-01-26 05:58 UTC2023-01N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-123bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-123a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08N210821-001AB1184e616aacf4f…
2026-08-18 06:07:402026-07N210821-001AB11caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N210821-001AB11011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N210821-001AB1131067a03dcf5…
2025-08-23 18:47 UTC2025-08N210821-001AB116a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N210821-001AB11fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N210821-001AB11b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N210821-001AB1103ed91905a0d…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N210821-001AB11a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
0777b696-474d-cd0d-e063-6294a90ae91f0a988ff2-88a8-4929-b524-4c8efef9c6012023-10-11Warnings, Adverse reactionsExact identifier
spl set id: 0a988ff2-88a8-4929-b524-4c8efef9c601

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.